Kadmon (KDMN) & Its Rivals Critical Review
Kadmon (NYSE: KDMN) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its rivals? We will compare Kadmon to similar businesses based on the strength of its analyst recommendations, earnings, valuation, dividends, profitability, institutional ownership and risk.
Risk & Volatility
Kadmon has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, Kadmon’s rivals have a beta of 1.08, meaning that their average share price is 8% more volatile than the S&P 500.
This table compares Kadmon and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Kadmon||$26.06 million||-$208.75 million||-1.98|
|Kadmon Competitors||$564.12 million||$96.17 million||58.18|
Kadmon’s rivals have higher revenue and earnings than Kadmon. Kadmon is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Kadmon and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations and price targets for Kadmon and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Kadmon presently has a consensus target price of $9.75, indicating a potential upside of 180.98%. As a group, “Biopharmaceuticals” companies have a potential upside of 13.78%. Given Kadmon’s higher probable upside, equities research analysts clearly believe Kadmon is more favorable than its rivals.
Institutional & Insider Ownership
51.9% of Kadmon shares are owned by institutional investors. Comparatively, 43.5% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 8.4% of Kadmon shares are owned by company insiders. Comparatively, 15.5% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Kadmon rivals beat Kadmon on 7 of the 12 factors compared.
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.
Receive News & Ratings for Kadmon Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.